EBMT-EHA 6th European CAR T-Cell Meeting 2024: Advancing Treatments and New Frontiers
In recent years, chimeric antigen receptor (CAR) T-cell therapies have revolutionized hemato-oncology. They have greatly improved outcomes of patients with B-cell malignancies and, with some challenges still existing, their potential continues to be explored in novel modalities and indications. The...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-06-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2024.20.148 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | In recent years, chimeric antigen receptor (CAR) T-cell therapies have revolutionized hemato-oncology. They have greatly improved outcomes of patients with B-cell malignancies and, with some challenges still existing, their potential continues to be explored in novel modalities and indications. The sixth European CAR T-cell Meeting convened in Valencia, Spain, drawing over 1,200 international experts, researchers and clinicians, underscored the expanding impact and future potential of this transformative treatment modality. Discussions focused on overcoming the challenges related to resistance and optimizing design and manufacturing. Furthermore, they highlighted the pivotal role of CAR T-cell therapy in hematologic malignancies, exploring key themes such as its efficacy in multiple myeloma and novel approaches to treat acute leukemia, alongside their potential in new frontiers, such as solid tumors and autoimmunity.
PEER REVIEWED ARTICLE
**Peer reviewers:**
Prof. Dr Antonia Müller, Medical University of Vienna, Vienna, Austria
Dr Vasiliki Papadopoulou, University Hospital Zurich, Zurich, Switzerland
One anonymous peer reviewer
Received on April 22, 2024; accepted after peer review on June 20, 2024; published online on June 28, 2024. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |